Recombinant Human OX40/TNFRSF4 Fc Chimera Protein, CF Best Seller

R&D Systems, part of Bio-Techne | Catalog # 3388-OX

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
3388-OX-050
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

NS0

Accession #

P43489

Structure / Form

Disulfide-linked homodimer

Conjugate

Unconjugated

Applications

Binding Activity

View all OX40 Proteins and Enzymes »

Product Specifications

Source

Mouse myeloma cell line, NS0-derived human OX40 protein
Human OX40
(Leu29-Ala216)
Accession # P43489		 IEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus

Purity

>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Leu29

Predicted Molecular Mass

46.7 kDa (monomer)

SDS-PAGE

63-69 kDa, reducing conditions

Activity

Measured by its binding ability in a functional ELISA.
When Recombinant Human OX40/TNFRSF4 Fc Chimera is immobilized at 10 ng/mL, the concentration of Recombinant Human OX40 Ligand/TNFSF4 (Catalog # 1054-OX) that produces 50% optimal binding response is found to be approximately 0.5-3 ng/mL.

Reviewed Applications

Read 5 reviews rated 5 using 3388-OX in the following applications:

Formulation, Preparation and Storage

3388-OX
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution
Reconstitute at 100 μg/mL in sterile PBS.

Reconstitution Buffer Available:
Size / Price
Qty
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: OX40

OX40 (CD134; TNFRSF4) is a T cell co-stimulatory molecule of the TNF receptor superfamily that coordinates with other co-stimulators (CD28, CD40, CD30, CD27 and 4-1BB) to manage the activation of the immune response (1-3). Human OX40 is a 48 kDa type I transmembrane glycoprotein with a 28 amino acid (aa) signal sequence, a 185 aa extracellular domain (ECD) that contains a cysteine-rich region, a 20 aa transmembrane segment, and a 41 aa cytoplasmic domain (4). The ECD of human OX40 shares 63% sequence identity with the ECD of mouse and rat OX40. OX40 is up-regulated on CD4+ and CD8+ T cells upon engagement of the TCR by antigen presenting cells along with co-stimulation by CD40-CD40 Ligand and CD28-B7 (5, 6). OX40 Ligand is primarily expressed on antigen presenting cells (5). OX40 Ligand engagement of OX40 on activated CD4+ T cells results in increased T cell survival, proliferation, and cytokine production. It also inhibits the conversion of effector T cells into immunosuppressive regulatory T cells (Tregs) and can promote the maintenance of and recall response in memory T cells (3, 7-10). OX40 is constitutively expressed on Tregs and enhances the sensitivity of Tregs to IL-2, thus promoting Treg proliferation. OX40 has also been shown to decrease the cells’ immunosuppressive activity on effector T cells (11-14). OX40-OX40 Ligand signaling is involved in allergic airway inflammation, graft-versus-host disease and autoimmune disease (6, 15, 16). Mutations in OX40 and OX40 Ligand are associated with cardiovascular disease (17, 18).

References

  1. Hori, T. (2006) Int. J. Hematol. 83:17.
  2. Latza, U. et al. (1994) Eur. J. Immunol. 24:677.
  3. Salek-Ardakani, S. et al. (2003) J. Exp. Med. 198:315.
  4. al-Shamkhani, A. et al. (1996) Eur. J. Immunol. 26:1695.
  5. Moran, A.E. et al. (2013) Curr. Opin. Immunol. 25:230.
  6. Gramaglia, I. et al. (1998) J. Immunol. 161:6510.
  7. Xiao, X. et al. (2008) J. Immunol. 181:3193.
  8. So, T. and M. Croft (2007) J. Immunol. 179:1427.
  9. Mousavi, S.F. et al. (2008) J. Immunol. 181:5990.
  10. Bansal-Pakala, P. et al. (2001) Nat. Med. 7:907.
  11. Piconese, S. et al. (2010) Eur. J. Immunol. 40:2902.
  12. Griseri, T. et al. (2010) J. Exp. Med. 207:699.
  13. Xiao, X. et al. (2012) J. Immunol. 188:892.
  14. Vu, M.D. et al. (2007) Blood 110:2501.
  15. Damayanti, T. et al. (2010) Am. J. Respir. Crit. Care Med. 181:688.
  16. Xiao, X. et al. (2012) Nat. Immunol. 13:981.
  17. Nakano, M. et al. (2010) Cardiovasc. Res. 88:539.
  18. Ishii, N. et al. (2010) Adv. Immunol. 105:63.
  19. Godfrey, W.R. et al. (1994) J. Exp. Med. 180:757

Alternate Names

ACT-135, CD134, Ly-70, TNFRSF4, Txgp1, TXGP1L

Entrez Gene IDs

7293 (Human); 22163 (Mouse); 25572 (Rat); 102145978 (Cynomolgus Monkey)

Gene Symbol

TNFRSF4

UniProt

P43489

Additional OX40 Products

Product Documents for Recombinant Human OX40/TNFRSF4 Fc Chimera Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human OX40/TNFRSF4 Fc Chimera Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.